Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma

Xian Shu Gao, Xue Ying Qiao, Xiang Ran Yang, Jun-Ichi Asaumi, Zhi Guo Zhou, Ya Di Wang, Dao An Zhou, Jun Wan, Masahiro Kuroda, Kanji Kishi, Shoji Kawasaki, Yoshio Hiraki

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The purpose of this study was to examine whether combined cisplatin and late course accelerated fractionation radiotherapy (LCAH) (the combined group) can confer a better outcome over LCAH alone in treating esophageal carcinoma. Eighty-one eligible patients were randomly entered into two groups: the LCAH alone group, and the combined group. There was a better outcome in the combined group compared to the LCAH group, but the difference was not significant. The combined therapy could significantly improve the survival rate and local control of the disease in the early stage, but not in the advanced stage, because of the possibility of invasion. More severe complications occurred in the combined group than in the LCAH group, but they were within tolerance. In conclusion, LCAH concomitant with cisplatin could improve the survival of patients with esophageal cancer, especially in the early stage, as long as the side effects of the treatment are within tolerable limits.

Original languageEnglish
Pages (from-to)767-772
Number of pages6
JournalOncology Reports
Volume9
Issue number4
Publication statusPublished - Jul 2002

Fingerprint

Cisplatin
Radiotherapy
Carcinoma
Esophageal Neoplasms
Survival Rate
Survival
Therapeutics

Keywords

  • Accelerated hyperfractionation
  • Cisplatin
  • Esophageal neoplasms
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gao, X. S., Qiao, X. Y., Yang, X. R., Asaumi, J-I., Zhou, Z. G., Wang, Y. D., ... Hiraki, Y. (2002). Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma. Oncology Reports, 9(4), 767-772.

Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma. / Gao, Xian Shu; Qiao, Xue Ying; Yang, Xiang Ran; Asaumi, Jun-Ichi; Zhou, Zhi Guo; Wang, Ya Di; Zhou, Dao An; Wan, Jun; Kuroda, Masahiro; Kishi, Kanji; Kawasaki, Shoji; Hiraki, Yoshio.

In: Oncology Reports, Vol. 9, No. 4, 07.2002, p. 767-772.

Research output: Contribution to journalArticle

Gao, XS, Qiao, XY, Yang, XR, Asaumi, J-I, Zhou, ZG, Wang, YD, Zhou, DA, Wan, J, Kuroda, M, Kishi, K, Kawasaki, S & Hiraki, Y 2002, 'Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma', Oncology Reports, vol. 9, no. 4, pp. 767-772.
Gao, Xian Shu ; Qiao, Xue Ying ; Yang, Xiang Ran ; Asaumi, Jun-Ichi ; Zhou, Zhi Guo ; Wang, Ya Di ; Zhou, Dao An ; Wan, Jun ; Kuroda, Masahiro ; Kishi, Kanji ; Kawasaki, Shoji ; Hiraki, Yoshio. / Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma. In: Oncology Reports. 2002 ; Vol. 9, No. 4. pp. 767-772.
@article{30121e55e5e044be9abc0ffb71f22145,
title = "Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma",
abstract = "The purpose of this study was to examine whether combined cisplatin and late course accelerated fractionation radiotherapy (LCAH) (the combined group) can confer a better outcome over LCAH alone in treating esophageal carcinoma. Eighty-one eligible patients were randomly entered into two groups: the LCAH alone group, and the combined group. There was a better outcome in the combined group compared to the LCAH group, but the difference was not significant. The combined therapy could significantly improve the survival rate and local control of the disease in the early stage, but not in the advanced stage, because of the possibility of invasion. More severe complications occurred in the combined group than in the LCAH group, but they were within tolerance. In conclusion, LCAH concomitant with cisplatin could improve the survival of patients with esophageal cancer, especially in the early stage, as long as the side effects of the treatment are within tolerable limits.",
keywords = "Accelerated hyperfractionation, Cisplatin, Esophageal neoplasms, Radiotherapy",
author = "Gao, {Xian Shu} and Qiao, {Xue Ying} and Yang, {Xiang Ran} and Jun-Ichi Asaumi and Zhou, {Zhi Guo} and Wang, {Ya Di} and Zhou, {Dao An} and Jun Wan and Masahiro Kuroda and Kanji Kishi and Shoji Kawasaki and Yoshio Hiraki",
year = "2002",
month = "7",
language = "English",
volume = "9",
pages = "767--772",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma

AU - Gao, Xian Shu

AU - Qiao, Xue Ying

AU - Yang, Xiang Ran

AU - Asaumi, Jun-Ichi

AU - Zhou, Zhi Guo

AU - Wang, Ya Di

AU - Zhou, Dao An

AU - Wan, Jun

AU - Kuroda, Masahiro

AU - Kishi, Kanji

AU - Kawasaki, Shoji

AU - Hiraki, Yoshio

PY - 2002/7

Y1 - 2002/7

N2 - The purpose of this study was to examine whether combined cisplatin and late course accelerated fractionation radiotherapy (LCAH) (the combined group) can confer a better outcome over LCAH alone in treating esophageal carcinoma. Eighty-one eligible patients were randomly entered into two groups: the LCAH alone group, and the combined group. There was a better outcome in the combined group compared to the LCAH group, but the difference was not significant. The combined therapy could significantly improve the survival rate and local control of the disease in the early stage, but not in the advanced stage, because of the possibility of invasion. More severe complications occurred in the combined group than in the LCAH group, but they were within tolerance. In conclusion, LCAH concomitant with cisplatin could improve the survival of patients with esophageal cancer, especially in the early stage, as long as the side effects of the treatment are within tolerable limits.

AB - The purpose of this study was to examine whether combined cisplatin and late course accelerated fractionation radiotherapy (LCAH) (the combined group) can confer a better outcome over LCAH alone in treating esophageal carcinoma. Eighty-one eligible patients were randomly entered into two groups: the LCAH alone group, and the combined group. There was a better outcome in the combined group compared to the LCAH group, but the difference was not significant. The combined therapy could significantly improve the survival rate and local control of the disease in the early stage, but not in the advanced stage, because of the possibility of invasion. More severe complications occurred in the combined group than in the LCAH group, but they were within tolerance. In conclusion, LCAH concomitant with cisplatin could improve the survival of patients with esophageal cancer, especially in the early stage, as long as the side effects of the treatment are within tolerable limits.

KW - Accelerated hyperfractionation

KW - Cisplatin

KW - Esophageal neoplasms

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0036633537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036633537&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 767

EP - 772

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -